EQ - Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.

52W High

$2.35

52W Low

$0.27

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.57

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

1.53

EV/EBITDA (<8 favorable)

0.07

EV/Revenue (<3 favorable)

6.19

P/S (TTM) (<3 favorable)

6.87

P/B (<3 favorable)

22.48

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

21.55%

Institutions (25–75% balanced)

11.74%

Shares Outstanding

59,503,000

Float

42,075,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

16,553,000

Gross Profit (TTM)

16,553,000

EPS (TTM)

-0.57

Profit Margin (>10% good)

-1.22%

Operating Margin (TTM) (higher better)

-1.24%

ROE (TTM) (>15% strong)

-1.47%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.52

Momentum

Bearish momentum

Value

0.3027

0.3215

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025